Harkness Project Title: Impact of Pharmaceutical Policies and Practice Guidelines on Costs and Quality
Biography at time of Harkness Fellowship: Steven Morgan, a 2001–2002 Canadian Associate of The Commonwealth Fund Harkness Fellowships in Health Care Policy, is a Canadian Institutes for Health Research post-doctoral fellow in health economics and is teaching and conducting research at McMaster University in Hamilton, Ontario, and at the University of British Columbia in Vancouver. Morgan’s research includes projects related to the economic aspects of direct-to-consumer drug advertising, drug price regulation, pharmaceutical patents, Canada-U.S. drug price differentials, and pharmaceutical insurance programs. He has published work (with Robert Evans and Morris Barer) on pharmaceutical policy and health economics and has been a consultant to federal and provincial governments in Canada. A recipient of the National Health Research and Development’s Ph.D. Fellowship and the Canadian Institutes of Health Research’s post-doctoral fellowship, Morgan obtained an M.A. in economics at Queen's University and a Ph.D. in economics at the University of British Columbia.
Project: Morgan’s project aimed to quantify the relative and absolute importance of different factors contributing to increases in per capita prescription drug costs for the population of Canadian seniors covered under the British Columbia Pharmacare Plan A. He conducted a quantitative analysis of prescription drug claims between 1985 and 1999, examining four components of expenditure inflation: the pattern of exposure to drugs across therapeutic categories; the mix of drugs used within therapeutic categories; the rate of generic drug product selection; and the prices of unchanged products.
Career Activity Since Fellowship
Current Position: Associate Director, Centre for Health Services and Policy Research, and Professor, School of Population and Public Health, University of British Columbia. (Updated 1/2014)
Morgan, S.” International Best Practices For Negotiating ‘Reimbursement Contracts’ With Price Rebates From Pharmaceutical Companies” Health Affairs 2013; 32 (4).
Morgan SG, Smolina K, Mooney D, Raymond C, Bowen M, Gorczynski C, et al. Canadian Rx Atlas, 3rd Edition. 3rd ed. Centre for Health Services and Policy Research; 2013.
Law M., Cheng L, Dhalla IA, Heard D, Morgan SG. The effect of cost on adherence to prescription medications in Canada. CMAJ. 2012;184(3):297-302.
Greyson DL, Cunningham C, Morgan SG. Information behaviour of Canadian pharmaceutical policy makers. Health Information and Libraries Journal. 2012;29(1):16-27.
Daw JR, Mintzes B, Law M., Hanley GE, Morgan SG. Prescription drug use in pregnancy: a retrospective, population-based study in british columbia, Canada (2001-2006). Clinical Therapeutics. 2012;34(1):239-249.e2.
Daw JR, Morgan SG. Stitching the gaps in the Canadian public drug coverage patchwork?: a review of provincial pharmacare policy changes from 2000 to 2010. Health Policy. 2012;104(1):19-26.
S. Morgan, et al., “The Cost of Drug Development: A Systematic Review,” Health Policy, April 2011.
Morgan M, Kennedy J. Prescription Drug Accessibility and Affordability in the United States and Abroad. The Commonwealth Fund, June 2010.
Kennedy, J., and Morgan S. “Cost-Related Prescription Nonadherence in the United States and Canada: A System-Level Comparison Using the 2007 International Health Policy Survey in Seven Countries” Clinical Therapeutics 2009; 31(1): 213-219
Morgan, S., Kennedy J, Boothe K, McMahon M, Roughead E., and Watson D. “Toward an understanding of high performance pharmaceutical policy systems: a ‘triple-A’ framework and example analysis” The Open Health Services and Policy Journal 2009; 2: 1-9.
Morgan, S., McMahon M, and Greyson D. “Balancing health and industrial policy objectives in the pharmaceutical sector: Lessons from Australia.” Health Policy 2008; 87: 133–145
Morgan, S., McMahon, M. and Mitton, C. "Centralizing Drug Review To Improve Coverage Decisions: Economic Lessons From (And For) Canada," Applied Health Economics and Health Policy 2006; 5(2): 67–73.
Morgan S, "Implications of Expenditures on Care: Prescription Drug Expenditures and Population Demographics," Health Services Research, April 2006 41(2):411–28.
Kennedy, J., and Morgan, S. "Health Care Access in Three Nations: Canada, Insured America, and the Uninsured America," International Journal of Health Services 2006; 36(4):697–717.
Morgan S.G. (2005) "Canadian prescription drug costs surpass $18 billion," Canadian Medical Association Journal, 172(10);1321–1324.
Morgan S.G. (2005) "Provincial drug spending: Different Levels, Similar, Trends," Healthcare Policy 1(1):85–99.
Morgan S, Bassett K, et al. (2005) "Are breakthrough drugs driving, pharmaceutical expenditures? Evidence from Canada," British Medical Journal, 331(7520):815-816.
Mintzes B, Morgan S and Bassett K. (2005) "Medicine by media: did a critical television documentary affect prescribing of cyproterone-estradiol (Diane-35)?" Canadian Medical Association Journal, 173(11):1313–1315.
Morgan SG, Schaub P, Mooney D et al. "The British Columbia Rx Atlas," UBC Centre for Health Services and Policy Research, December 2005.
Morgan SG, McMahon M, Lam D, et al. "The Canadian Rx Atlas," UBC Centre for Health Services and Policy Research, December 2005.
Morgan SG. Booming Prescription Drug Expenditure: A Population-Based Analysis of Age Dynamics. Medical Care, 43(10):996–1008, October 2005.
Morgan S. "Drug Spending in Canada: Recent Trends and Causes," Medical Care, 42(7):635–642, July 2004.
Morgan, S, Bassett K, and Mintzes B, "Outcomes-Based Drug Coverage in British Columbia: A Unique Approach to Public Drug Coverage That Uses Academic Advisers and Saves Money," Health Affairs 2004; 23(3): 269–276.
Abelson J, Mendelsohn M, Lavis JN, Morgan SG, Forest P-G, Swinton M. "A 2002 Survey Shows That Canadians' Attitudes Towards Health System Changes Are in a State of Flux," Health Affairs 2004; 23(3): 186–193.
Morgan, S, Agnew J, and Barer M, "Seniors' Prescription Drug Cost Inflation and Cost Containment: Evidence from British Columbia," Health Affairs May/June 2004.
Barer, M, Morgan S, Evans B. (2003) "Strangulation or Rationalization? Costs and Access in Canadian Hospitals," Longwoods Review, 1(4):10–19.
Morgan S, Mintzes B, Barer M, "Will Direct-to-consumer Advertising Improve Consumer Welfare?" Journal of Health Services Research and Policy, 2003; 8(4):237–244.
Morgan S. "Statistics and drug utilization: Are prescribing rates really that high?" Canadian Medical Association Journal 165(11):507–1508. 2001.
Morgan, S., "Drug Spending in Canada: Recent Trends and Causes," Medical Care.